

Original Research Article

Prevalence of multi drug resistant *Klebsiella pneumoniae* infections, causing a HAVOC in intensive care units of a tertiary care hospital

Vaibhavi Subhedar¹, Sherebano Bandoowala², Sudhir Kumar Jain³

¹Consultant Microbiologist and Infection Control Incharge, Bombay Hospital Indore MP. P.Hd Research Scholar School of Studies in Microbiology Vikram University, Ujjain, MP

²Post PG Student, M.Sc Microbiology, School of Studies in Microbiology Vikram University, Ujjain, MP

³Associate Professor, School of Studies in Microbiology Vikram University, Ujjain, MP

*Corresponding author

Vaibhavi Subhedar

Email: vaibhavisubhedar14@rediffmail.com

Abstract: Multi drug resistance *Klebsiella pneumoniae* are rapidly emerging as life threatening nosocomial infections. The ICUs are considered as epicenter of infection mainly because of severe clinical conditions, increasing use of invasive diagnostic procedures lapses in sterilization and disinfections. Beta-lactamase which include ESBL, AMPC, CARBAPENAMASES, MBL have emerged as the most worrisome mechanism of resistance amongst the gram negative bacteria which pose a therapeutic challenge to health care institutes. This study aims to find the prevalence of MDR *Klebsiella pneumoniae* isolates from various clinical specimens of ICU patients and to evaluate their sensitivity patterns. The present study was a retrospective study of a 50 bedded ICU in tertiary care hospital from August 2014 to May 2015. Out of total 500 different clinical specimens studied 288 (57.6 %) specimens showed growth of *Klebsiella species*. Phenotypic characterizations of Beta lactamases present in *Klebsiella* isolates were carried out by disc diffusion methods (CLSI guidelines). The prevalence of Beta lactamase genes in 25 strains of *Klebsiella* was also studied using multiplex PCR. Antibiotic susceptibility was performed according to the CLSI guidelines. Among the total of 500 isolates from ICU 288 (57.6 %) isolates were *Klebsiella* maximum being isolated from tracheal specimens. The most common βlactamase identified was AMPC 151 (52.43%), followed by carbapenemes 45 (15.62%), ESBL 31 (10.76%), (7.29%), MBL 5 (1.73%), unknown 25 (%), Coproduction of ESBL +AMPC 17(5.90%), AMPC+CARBAPENAMASES 8 (2.77%), AMPC +MBL 4 (1.38%) was detected phenotypically and similar results were found genotypically.

Keywords: Beta lactamases, MDR, tertiary care, ICUs, *Klebsiella pneumoniae*.

INTRODUCTION

The aim of the present study was to conduct surveillance in the Intensive care Unit of a tertiary care hospital in Indore to study the prevalence of multi drug resistant *Klebsiella pneumoniae* [2]. The Intensive care unit's is called the epicenter of infection, due to its extremely vulnerable population which are associated with severe clinical conditions along with the impaired immunity increased risk of becoming infected through multiple procedures and use of invasive devices distorting the anatomical integrity, lapses in infection control practices and indiscriminate use of antibiotics. Multi drug resistant *Klebsiella pneumoniae* is increasingly being reported worldwide [1]. Multi drug resistant *Klebsiella pneumoniae* is associated with high morbidity and mortality [7]. The *Klebsiella pneumoniae* species in addition to its virulences and ability to acquire antibiotics resistance determinants are able to survive on skin and water surface and resist desiccation which adds to its pathogenicity [7]. Multi drug resistant

Klebsiella pneumoniae sepsis has serious implications because of limited choices of antibiotics available [7]. *Klebsiella pneumoniae* is a well described health care associated pathogen and a cause of sepsis, urinary tract infections, Pneumonia, and soft tissues infection in patients in the Intensive care unit's [8]. The most common reservoir for these pathogens appears to be the gastrointestinal tract of colonized patient, and patient-to-patient transmission is facilitated by transient or resistant hand carriage of health care workers (HWCs) [8]. Antibiotics resistance is a major world wide problem in the Intensive care units [6]. The treatment of multi drug resistant bacterial infection such as the MBL, AMPC, ESBL, CARBAPENAMASE, producing. *Klebsiella pneumoniae* is a major concern to clinicians and continues to be problematic. Clinically these pathogens are becoming more and more resistant to the old and some of the more recently developed antimicrobial agents due to non availability of mechanisms to fight resistances [3]. These strains are

difficult to control because they spread easily within and between hospitals and treatment options for multi drug resistant infections are extremely limited [1]. Strategies to control outbreaks have included antibiotic control policies, cohorting infected and colonized patients, transmission-precautions, surveillance cultures of patients, the environments and HCW's and improving hand hygiene [2].

MATERIALS AND METHODS

The present study was conducted in the department of microbiology of tertiary care hospitals in Indore. A total of 500 specimens were included in the study from August 2014 to MAY 2015. The specimens included blood, sputum, pus, endotracheal secretions, urine, fluids etc. 288 specimens showed growth of *Klebsiella pneumoniae*. All the isolates were characterized to species level using standard procedures. Organism collection, transport, confirmation, of organism identification and development and management of a centralized data base were coordinated by microbiology department of Bombay hospital Indore India.

BactT alert 3D (biomerivex, france) automated system was used to culture all the blood sample received. Blood culture bottled were incubated for seven day before being reported negative, identification and antibiotics susceptibility testing of all these isolates were done using routine biochemical tests and standard Kirby-baurers methods for antibiotics susceptibility and subsequently and interpreted as per CLSI guidelines. Isolates from positive culture showing growth of *Klebsiella pneumoniae* were included in the study.

Antimicrobial susceptibility study

The antimicrobial susceptibility listing of the drugs were determined by the disc diffusion method according to the clinical laboratory standards institute methods (CLSI). Quality controls (QC) were performed on each day of testing using ATCC standard strains as the reference strains throughout study [2]. The strains were typed on the basis of antibiogram.

Phenotypic Detection of enzymes producing organisms

All the antibiotics disc were procured from Hi-media Mumbai. The strains were tested for ESBL production by phenotypic confirmatory disc diffusion test (PCDDT) AMPC production by AMPC disk test and carbapenamases production by modified Hodge test. MBLs the metallo- β -lactames production was detected by the imipenem EDTA double disk synergy test.

Detection of ESBLs

Each strains was screened for the ESBL producing against cefotaxime, ceftazidime. The strains which were resistant to these third generation cephalosporins were confirmed by these phenotypic test i.e the disc potentiation test (by using ceftazidime & ceftazidime-clav, cefotaxime and cefotaxime clav discs), the double disc synergy test as per the CLSI guideline [4]. The strains showing a difference of ≥ 5 mm were considered as ESBL producing.

Detection of AMPC Beta- Lactames

All the strains were screened for the AMPC - β -LACTAMES production by the disc antagonism test. Using cefoxitin and cefoxitin+cloxacillin disc diffusion method [4]. A difference of 4mm or more was considered as positive for AmpC production.

Detection of Metallo-Beta-Lactamases (MBLs)

The metallo-Beta-lactamase production was detected by the Imipenem-EDTA double disc synergy test. The organism were considered to be MBL Producers if they showed a difference of >7 mm in the zone size of Imipenem=Imipenem EDTA.[4].

Modified Hodge Test

The strains were subject to modified Hodge test for detection of carbapenamase. An overnight culture suspension of *E. coli* ATCC 25922 adjusted of 0.5 MC.FARLAND standard was inoculated using a sterile cotton swab on the surface of a Muller-Hinton agar. After drying 10mg meropenems disk was placed at the center of the plate and the test strains were streaked from the edge of the disk to the periphery of the plate in four different directions. The plates were incubated overnight at 37c. The presence of a (clover leaf shaped) zone of inhibition due to carbapenams production by the test strains was considered as positive [7].


Genotypic Detection of Beta Lactamase Genes:

For the genotypic detection 25 strains of MDR *Klebsiella pneumoniae* were outsourced where Multiplex PCR test was performed for the detection of ESBL (SHV,TEM and CTX-M type genes), AmpC gene and MBL gene(*blaIMP*, *blaVIM*, *blaNDM-1*).

Statistical analysis

The results obtained were subjected to statistical analysis for the detection of Mean absolute error for MDR *Klebsiella pneumoniae* producing different Beta lactamases and the value was 0.989 which is \leq to 1.


RESULTS




Graph-1: Specimens wise distribution.

Table-1: Specimen Wise Distribution.

SERIAL NUMBERS	SPECIMENS NAME	TOTAL ORGANISMS	<i>KLEBSIELLA PNEUMONIAE</i>
1	BLOOD	42	27
2	URINE	121	39
3	PUS	56	39
4	ET/TT	234	152
5	SPUTUM	34	27
6	BAL	1	0
7	DRAIN FLUID	1	2
8	STOOL	8	0
9	UNNECLS	1	0
10	WOUND	1	2
11	DRAIN TIP	1	0



Graph -2



Graph-3:

Table-2: Phenotypic Detection of Beta Lactamases

S. No	Enzymes	Value	Percentage
1	AMPC	151	52.43
3	MBL	5	1.73%
4	CARBA	45	15.62%
5	ESBL	31	10.76%
6	UNKNOWN	25	8.68%
7	AMPC+CARBA	8	2.77%
8	AMPC +MBL	4	1.38%
9	ESBL+AMPC	17	5.90%

Table-3: Genotypic detection of Beta lactamases by Multiplex PCR:

SHV	ESBL(12) TEM	CTX-M	AmpC(8)	NDM-1	MBL(5) VIM	IMP
9	10	1	8	3	2	0

Table-4: Sensitivity Pattern of MDR Klebsiella SP

Antibiotics	ESBL-31	AMPC-151	MBL-5	CARBAPENAMES-45	UNKNOWN-25
COLISTIN	31(100%)	151(100%)	5(100%)	35(77.77%)	25(100%)
MEROPENEM	26(83.87%)	115(76.15%)	0	0	23(92%)
IMEPENEM	24(77.41%)	138(91.39%)	0	27(60%)	14(56%)
TIGECYCLINE	31(100%)	151(100%)	5(100%)	45(100%)	0
PIP+TAZO	22(70.96%)	0	0	0	0
AMIKACIN	22(70.96%)	56(37.08%)	2(40%)	9(20%)	9(36%)
CEFO+SULBACTUM	23(74.19)	0	0	0	0
CHLORAMPHENICOL	0	83(54.96%)	0	0	22(88%)
TOBRAMYCIN	0	42(27.81%)	0	10(22.23%)	0
ERTAPENEM	0	0	0	0	13(52%)
LEVOFLOX	0	0	0	0	8(32%)
TETRACYCLINE	0	0	0	15(33.33%)	0
NETILMYCIN	0	0	1(20%)	8(17.77%)	0
POLYMXIN B	0	0	5(100%)	0	0

During the study period a total 288 *Klebsiella pneumoniae* were isolated from a range of clinical specimens of patient's hospitalized in ICU's of a tertiary care hospital.

Klebsiella pneumoniae isolates were frequently isolated from respiratory specimens ET/TT (152), followed by Urine(39), Pus(39), Blood(27), Sputum(27), Fluid (2),Wound(2) shown in Graph 1.

As shows table 2 phenotypic detection of beta lactamases revealed high AMPC production 151/288 (52.43%), followed by Carbapenemases 45/288(15.62%), ESBL31/288(10.76%), UNKNOWN 25/288(8.68%), MBL5(1.73%),co-production of ESBL+AMPC was found in 17(5.90%) , followed by AMPc+Carbapenamase 8/288(2.77%), AMPc+MBL 4/288(1.38%) as shown in Graph 2&3.

Genotypic detection of resistant genes by multiplex PCR in 25 selected strains revealed a higher ESBL production with SHV and TEM types of ESBLs more prominent as shown in Table no4. A striking feature was a high rate of co production of more than 2 genes i.e ESBLs+AmPC +MBL which is a matter of concern.

Sensitivity pattern of the MDR *Klebsiella* as shown in Table no 5 indicates a higher resistance towards 3rd generation cephalosporins, quinolones. Common sensitivity for ESBLs was Meropenem, Imipenem, Colistin Amikacin and Pip+Tazo. Similarly for AmpC were Imipenem, Meropenem, Chloramphenicol, Colistin and Tobramycin. For MBLs the sensitivity was towards Colistin, Tigecycline, Polymyxin B.

DISCUSSION

The infection caused by multidrug resistant *Klebsiella pneumoniae* that produced various beta lactamase enzymes have been reported with in increasing frequency in the ICU's and are associated with a significant increases morbidity and mortality [4, 2]. *Klebsiella pneumoniae* is a recognized of hospital acquired infection worldwide [16] & becomes a global challenge as this organisms is resistant to cephalosporine, Amyglucosides, fluoro-quinolones, and Now emergines of carbapenem, resistance in this species is off considerable concern, living relatively in limited treatment options from ICU's infection [2]. The patient's in ICU are more prone to colonization and infection by the various pathogens [9] and *Klebsiella pneumoniae* species commonest isolates which cause infection in such patients [2]. The numerous beta lactamases are encoded by either by the chromosomal gene or transferable are encoded which are located on the plasmids or the transposons [4]. In our study nearly 57.6% of ICU infections were caused by

Klebsiella pneumoniae. Similarly study reported the incident of *Klebsiella pneumoniae* 55-77% [15, 14, 9, 16]. The beta-lactamases producing in this *Klebsiella species* were AMPC 52.45%, CARBAPENAMES 15.62%, ESBL-10.76%, ESBL+AMPC- 5.90%, AMPC+CARBAPENAMES-2.77%, AMPC+MBL-1.38%, UNKNOWN-8.68%, MBL-1.38%.

Similar report were seen by Bandlekar *et al.* [18] (22.9%) of AMPC production and by Battarcharji *et al.* showing 22% production [17]. The high prevalence of AMPC production in our study may be due to differences in the geographical distribution resulting in variations.

In the prevalence of Beta-lactamases co-production detected phenotypically was ESBL+AmPC 17(77%), AMPC+MBL (1.38%).

Similarly results were seen by Loweena *et al.* [4]. The co-existence of different class of beta-lactamases may pose diagnostic and treatment challenges the AMPC producing organisms' can act as reservoir and high level expressions of AMPC may mask the reorganized of ESBL's resulting in fatal and in appropriate antimicrobial therapy.

CONCLUSION

In the present study *Klebsiella pneumoniae* was a predominant multi drug resistant organism isolated from the ICUs of the tertiary care center. A high prevalence of ESBL and AmpC producing strains were observed and an increasing prevalence of coexistence of genes was also observed in both phenotypic and genotypic methods which result in failure of antimicrobial therapy. In this respect, antimicrobial stewardship and infection control measures are urgently needed for controlling the spread of MDR infections in ICUs.

REFERENCES

1. Hu Y, Ping Y, Li L, Xu H, Yan X, Dai H. A retrospective study of risk factors for carbapenem-resistant *Klebsiella pneumoniae* acquisition among ICU patients. The Journal of Infection in Developing Countries. 2016 Mar 31;10(03):208-13.
2. Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing *Acinetobacter baumannii* in Indian intensive care units. Journal of Pharmacy Research. 2013 Feb 28;7(2):175-80.
3. Kumar MS, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian journal of medical microbiology. 2006 Jul 1;24(3):208.
4. Oberoi L, Singh N, Sharma P, Aggarwal A. ESBL, MBL and Ampc β lactamases producing

- superbugs–Havoc in the Intensive Care Units of Punjab India. Journal of clinical and diagnostic research: JCDR. 2013 Jan;7(1):70.
5. Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant *Klebsiella pneumoniae* along the continuum of care, Los Angeles County. Population. 2013 Feb;34(2):144-50.
 6. Dewan S, Sahoo T, Chandra N, Varma A. Prevalence of multidrug resistance, extensive drug resistance and pandrug resistance among multiple Gram-negative isolates: experience in a tertiary-care hospital ICU in North India. Critical Care. 2013 Mar 19;17(2):1.
 7. Kaur J, Sheemar S, Chand K, Chopra S, Mahajan G. Outbreak of Carbapenemase-Producing *Klebsiella pneumoniae* Blood Stream Infections in Neonatal Intensive Care Unit. Int. J. Curr. Microbiol. App. Sci. 2016;5(1):727-33.
 8. Gupta A, Della-Latta P, Todd B, San Gabriel P, Haas J, Wu F, Rubenstein D, Saiman L. Outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a neonatal intensive care unit linked to artificial nails. Infection Control & Hospital Epidemiology. 2004 Mar 1;25(03):210-5.
 9. Harakuni S, Karadesai SG, Mutnal MB, Metgud SC. Prevalence of extended spectrum β -lactamase-producing clinical isolates of *Klebsiella pneumoniae* in intensive care unit patients of a tertiary care hospital. Annals of Tropical Medicine and Public Health. 2011 Jul 1;4(2):96.
 10. Datta S, Wattal C, Goel N, Oberoi JK, Raveendran R, Prasad KJ. A ten year analysis of multi-drug resistant blood stream infections caused by *Escherichia coli* & *Klebsiella pneumoniae* in a tertiary care hospital. The Indian journal of medical research. 2012 Jun 1;135(6):907.
 11. Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM, Anderson GJ, Williams PP, Brittain KL, Oliver A, McGowan JE, Tenover FC. Characterization of clinical isolates of *Klebsiella pneumoniae* from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum β -lactamase detection methods. Journal of Clinical Microbiology. 2001 Aug 1;39(8):2864-72.
 12. Daikos GL, Petrikos P, Psychogiou M, Kosmidis C, Vryonis E, Skoutelis A, Georgousi K, Tzouveleki LS, Tassios PT, Bamia C, Petrikos G. Prospective observational study of the impact of VIM-1 metallo- β -lactamase on the outcome of patients with *Klebsiella pneumoniae* bloodstream infections. Antimicrobial agents and chemotherapy. 2009 May 1;53(5):1868-73.
 13. Mantzaris K, Makris D, Manoulakas E, Karvouniaris M, Zakyntinos E. Risk factors for the first episode of *Klebsiella pneumoniae* resistant to carbapenems infection in critically ill patients: a prospective study. BioMed research international. 2013 Dec 18;2013.
 14. Manoharan A, Sugumar M, Kumar A, Jose H, Mathai D, ICMR-ESBL study group. Phenotypic & molecular characterization of AmpC β -lactamases among *Escherichia coli*, *Klebsiella* spp. & *Enterobacter* spp. from five Indian Medical Centers. The Indian journal of medical research. 2012 Mar 1;135(3):359.
 15. Ramazanzadeh R, Chitsaz M, Bahmani N. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran). Chemotherapy. 2009 Jun 10;55(4):287-92.
 16. Saleem AF, Qamar FN, Shahzad H, Qadir M, Zaidi AK. Trends in antibiotic susceptibility and incidence of late-onset *Klebsiella pneumoniae* neonatal sepsis over a six-year period in a neonatal intensive care unit in Karachi, Pakistan. International Journal of Infectious Diseases. 2013 Nov 30;17(11):e961-5.
 17. Bhattacharjee A, Anupurba S, Gaur A, Sen MR. Prevalence of inducible AmpC β -lactamase-producing *Pseudomonas aeruginosa* in a tertiary care hospital in northern India. Indian journal of medical microbiology. 2008 Jan 1;26(1):89.